India's NexCAR19 CAR-T Cell Therapy Receives Market Authorization

Recently, India's Central Drugs Standard Control Organisation (CDSCO) has granted market authorization for NexCAR19, the nation's first CAR-T cell therapy, marking a significant milestone in cancer treatment.

Key Points

  • CAR-T therapy modifies T-cells, turning them into potent cancer fighters, offering a revolutionary approach to cancer treatment.
  • Designed for B-cell lymphomas, NexCAR19 provides potential lifelong benefits and a one-time transformative therapy for non-responsive cancer patients.
  • The patient's journey involves a doctor's prescription, blood donation, genetic modification of T-cells in the lab, and reinfusion within 7-10 days.

Effectiveness Compared to Other Treatments

  • Contrast with chemotherapy and immunotherapy, emphasizing CAR-T's potential for a cure and ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Buy January 2024 Issue

Already a Member? Login here

Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Be an Annual Subscriber

Related Content